8/15/2007 11:40:29 AM
Glide PharmaTM, the specialty pharmaceutical company developing products based on its innovative needle-free Glide SDI™ drug delivery system, has raised £2.3 million. The round involved existing shareholders, such as Oxford Technology 4 VCT, as well as new investors including Oxford Capital Partners. Under a separate agreement, Glide Pharma has also entered into an exclusive licence and distribution deal with Paladin Labs Inc, a leading Canadian specialty pharmaceutical company, for Glide Pharma products in Canada.
comments powered by